Share on LinkedInShare on LinkedIn

ARTICLE · 18 JULY 2022

The European Bolar Exemption From Infringement

Under the so-called ‘Bolar' exemption, clinical trials for generics and biosimilars are exempt from infringement.

European UnionIntellectual Property

Under the so-called ‘Bolar' exemption, clinical trials for generics and biosimilars are exempt from infringement. In some European countries, including the UK, the exemption even extends to innovative products.

Introduction

In order to market a medicinal product, a manufacturer must first obtain regulatory approval by conducting clinical tests and trials to prove that the product is safe and effective. However, when the medicinal product is a generic (1) or biosimilar (2) product, a company can avoid having to carry out full trials by relying on at least some of the data submitted by the original applicant for marketing authorisation in connection with the original (reference) medicinal product. To use this so-called abridged procedure for obtaining marketing authorisation, however, it is necessary to demonstrate that the generic/ biosimilar version is bioequivalent to the approved reference medicine.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from